BPC-157

BPC-157 is a linear pentadecapeptide with the one-letter sequence GEPPPGKPADDAGLV. The molecular formula is C62H98N16O22 with an average molecular weight near 1419.5 Da and a theoretical monoisotopic mass of 1418.7128 Da. CAS registry: 137525-51-0.

The sequence is derived from a 62 kDa human gastric juice protein called Body Protection Compound (BPC); residues 1–15 of the parent define BPC-157. There is no native post-translational modification on this fragment, so all material in circulation is fully synthetic.

BPC-157 is produced by standard Fmoc solid-phase peptide synthesis (SPPS). Two regions of the sequence are responsible for most of the impurity burden:

• The Pro-Pro-Pro tract at positions 3–5. Proline is a difficult coupling partner because of steric hindrance at the secondary amine; three in a row is a well-documented source of deletion sequences and incomplete coupling.
• The Asp-Asp segment at positions 10–11. Aspartate is prone to aspartimide formation under repeated piperidine deprotection, which can rearrange to α- and β-aspartyl products and racemized D-Asp.

A complete impurity profile from a real batch typically includes deletion sequences, C-terminal truncations, D-Pro racemers, aspartimide-derived isomers, oxidation products from storage, and residual TFA counter-ion from cleavage. See common peptide impurities for the full taxonomy.

The standard CertikLabs panel for a BPC-157 batch:

• RP-HPLC purity (C18, 0.1% TFA / MeCN, UV 214 nm)
• LC-MS identity (ESI-Q-TOF, observed vs theoretical monoisotopic mass)
• Quantitative AAA for content
• Ion chromatography for TFA / acetate counter-ion
• Karl Fischer for water content

Each method, including column, mobile phase, gradient, and detection conditions, is reported on the Certificate of Analysis so the result is reproducible. See how to read a peptide COA for what each section should contain.

Published rodent literature describes activity on angiogenesis (VEGFR2 pathway), nitric oxide signaling, and growth-factor expression in injured tissue. No clinical efficacy or safety claims are made here.

Primary sources:

• Sikiric P. et al., Stable gastric pentadecapeptide BPC 157 — review.(PMID 29879886)
• Chang C.H. et al., BPC 157 promotes tendon outgrowth in vitro.(PMID 21030672)

CertikLabs does not publish dosing, administration routes, or clinical recommendations for BPC-157.

Lyophilized BPC-157 is generally stable at -20°C protected from light and moisture. Reconstituted in bacteriostatic or sterile water, stability is shorter and degradants (oxidation, deamidation, aggregation) accumulate; analytical re-test of any working solution is the only reliable confirmation.